Three of the catalogue's bioregulators share the same three residues, and the fourth shares two of them — which raises a question the tissue names do not answer. Vesugen is Lys-Glu-Asp. Prostamax and Testagen are that tripeptide with one residue added. Pinealon rearranges the same pieces into Glu-Asp-Arg. The names describe the extracts they were found in, not any known selectivity, and what the sequences share is more informative than what the names claim.
The four sequences
| Name | Sequence | Residues | Extract of origin | Net charge at pH 7 |
|---|---|---|---|---|
| Vesugen | Lys-Glu-Asp | 3 | Vascular tissue | −1 |
| Prostamax | Lys-Glu-Asp-Pro | 4 | Prostate | −1 |
| Testagen | Lys-Glu-Asp-Gly | 4 | Testis | −1 |
| Pinealon | Glu-Asp-Arg | 3 | Brain / pineal | −1 |
Every one carries one basic residue and two acidic ones, which gives all four the same net charge and very similar behaviour in solution. Chemically they are close relatives. Whatever distinguishes them biologically has to come from the order and the one variable residue, and that is a strong claim for a molecule of three or four residues to carry.
Where does the Lys-Glu-Asp motif come from?
From the programme's method. Tissue extracts were fractionated and short sequences that recurred were identified and synthesised. Lys-Glu-Asp appeared across several tissues, and the programme's interpretation was that the shared motif carried a general regulatory function while the additional residue conferred tissue specificity. That is a hypothesis, and it is the central one for this family. The alternative reading — that a common short acidic motif turned up in many extracts because it is a common short acidic motif — is not excluded by anything in the literature, and a rigorous programme would have tested it directly. The group as a whole rests on the same premise.
Can one residue make a tetrapeptide tissue-specific?
In principle a single residue can change what a peptide binds, and the melanocortin and secretagogue families show single substitutions shifting receptor selectivity substantially. But those are cases where a receptor is known and the substitution's effect on binding can be measured. For the bioregulators no receptor has been identified for any member, so the claim that Pro versus Gly at position four directs a peptide to prostate versus testis cannot currently be tested at the level where it would be established. It remains the programme's proposal, supported by the programme's tissue-model data and not yet by a mechanism.
Reading them as a set
The honest way to work with these four is to treat them as what the chemistry says they are: a family of closely related short acidic peptides, with a shared literature and a shared evaluation problem. Two things follow.
First, a result with one of them is a hypothesis about the others. If Vesugen produces an effect in a cell model, the same experiment with Prostamax and Testagen is the natural control — and the outcome, whichever way it goes, is informative about whether the additional residue matters.
Second, a null result with one is weak evidence about the family, since the relevant readout may be the one tissue system the name points at. That is the programme's own framing, and it makes the compounds difficult to disprove, which is a property worth noticing in itself.
How do they behave in the laboratory?
As nearly the simplest case possible, and identically to each other. All four are freely water-soluble, carry no cysteine, methionine or tryptophan, and have nothing to oxidise or fold. Their exposures are the two that follow from being tiny and unmodified: they are removed within minutes by any medium containing aminopeptidases, and at working concentration they lose a large fraction of themselves to a tube wall. Fresh solutions, low-binding tubes and short exposure windows are the whole of the handling advice.
One subtlety: at pH 4 or below the acidic residues protonate and the peptides approach neutrality, which is where solubility is lowest and aggregation most likely. Neutral buffer suits them better than the mildly acidic default that serves most short peptides.
What does a certificate for these look like?
Sparse, and correctly so. Identity by mass is clean — each has a small, exact theoretical mass, and Prostamax and Testagen differ by 40 daltons, which any instrument resolves easily. Purity by HPLC is straightforward for such small peptides, though very short sequences elute early and close to the solvent front, so the chromatogram should be read with that in mind. Net peptide content is the figure that carries the most weight, since a tripeptide's counter-ion burden is a large fraction of its mass. The panels are the usual ones; the only thing to check with particular care is that the identity mass matches the intended member of the family rather than a neighbour.
Which one should a study of the family start with?
Vesugen, on structural grounds: it is the shared core, and the other three are it plus something. An effect with the tripeptide alone establishes what the motif does; adding the fourth residue then tests what, if anything, the variable position contributes. Starting with one of the tetrapeptides folds both questions into one experiment and cannot separate them. This is the same logic as using the selective compound as the comparator in a receptor series, applied to a family where the receptor is unknown.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
